The FDA on August 3, 2012 approved ZALTRAPĀ® (Ziv-aflibercept injection), for use in combination with 5-fluorouracil, leucovorin, CAMPTOSARĀ® (Irinotecan) (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin containing regimen. ZALTRAPĀ® is a product of Sanofi U.S., Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
